Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst David Hoang maintains a Buy rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) but lowers the price target from $30 to $23.
August 08, 2024 | 7:26 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Citigroup analyst David Hoang maintains a Buy rating on ACADIA Pharmaceuticals but lowers the price target from $30 to $23.
The maintained Buy rating suggests continued confidence in ACADIA Pharmaceuticals' long-term prospects. However, the lowered price target indicates some concerns or adjustments in expectations, which could lead to mixed short-term reactions in the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100